Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510351 · ClinicalTrials.gov registry record
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
A clinical trial, sponsored by Temple University.
- Completed
- Registry status
- 200
- Enrollment target
NCT03510351 is a clinical trial that has completed, run by Temple University. The registered enrollment target is 200 participants.
The verdict
NCT03510351 has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
Interventions
- DRUG Ceftolozane-Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03510351
The ClinicalTrials.gov registry entry for NCT03510351 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceftolozane-Tazobactam is the first listed.
NCT03510351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03510351 about?
NCT03510351 is a clinical study titled "Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections". This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
What is the current status of trial NCT03510351?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2017-02-01. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT03510351?
The interventions under investigation include: Ceftolozane-Tazobactam (DRUG).
Who is sponsoring clinical trial NCT03510351?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.